Literature DB >> 33658540

The analysis of GSTA1 promoter genetic and functional diversity of human populations.

Tiago Nava1, Marc Ansari2,3, Vid Mlakar1, Patricia Huezo-Diaz Curtis1, Marc Armengol1, Victor Ythier4, Isabelle Dupanloup5, Khalil Ben Hassine1, Laurence Lesne1, Rabih Murr4, Simona Jurkovic Mlakar1.   

Abstract

GSTA1 encodes a member of a family of enzymes that function to add glutathione to target electrophilic compounds, including carcinogens, therapeutic drugs, environmental toxins, and products of oxidative stress. GSTA1 has several functional SNPs within its promoter region that are responsible for a change in its expression by altering promoter function. This study aims to investigate distributions of GSTA1 promoter haplotypes across different human populations and to assess their impact on the expression of GSTA1. PHASE 2.1.1 was used to infer haplotypes and diplotypes of six GSTA1 promoter SNPs on 2501 individuals from 26 populations classified by the 1000 Genomes Project into five super-populations that included Africa (N = 660), America (N = 347), East Asia (N = 504), Europe (N = 502), and South Asia (N = 488). We used pairwise FST analysis to compare sub-populations and luciferase reporter assay (LRA) to evaluate the impact of each SNP on activation of transcription and interaction with other SNPs. The distributions of GSTA1 promoter haplotypes and diplotypes were significantly different among the different human populations. Three new promoter haplotypes were found in the African super-population. LRA demonstrated that SNPs at -52 and -69 has the most impact on GSTA1 expression, however other SNPs have a significant impact on transcriptional activity. Based on LRA, a new model of cis-elements interaction is presented. Due to the significant differences in GSTA1 diplotype population frequencies, future pharmacogenomics or disease-related studies would benefit from the inclusion of the complete GSTA1 promoter haplotype based on the newly proposed metabolic grouping derived from the LRA results.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33658540      PMCID: PMC7930039          DOI: 10.1038/s41598-021-83996-2

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  36 in total

1.  The human glutathione transferase alpha locus: genomic organization of the gene cluster and functional characterization of the genetic polymorphism in the hGSTA1 promoter.

Authors:  Fabrice Morel; Claudine Rauch; Brian Coles; Eric Le Ferrec; André Guillouzo
Journal:  Pharmacogenetics       Date:  2002-06

2.  The GSTA1 polymorphism and cyclophosphamide therapy outcomes in lupus nephritis patients.

Authors:  Hong-Na Wang; Xiao-Ye Zhu; Ying Zhu; Qiong-Hong Xie; Lin-Yun Lai; Miao Zhao; Yuan-Cheng Chen; Jun Xue; Chuan-Ming Hao; Yong Gu; Shan-Yan Lin
Journal:  Clin Immunol       Date:  2015-07-26       Impact factor: 3.969

3.  GSTA1 Genetic Variants and Conditioning Regimen: Missing Key Factors in Dosing Guidelines of Busulfan in Pediatric Hematopoietic Stem Cell Transplantation.

Authors:  Tiago Nava; Mohamed A Rezgui; Chakradhara R S Uppugunduri; Patricia Huezo-Diaz Curtis; Yves Théoret; Michel Duval; Liane E Daudt; Marc Ansari; Maja Krajinovic; Henrique Bittencourt
Journal:  Biol Blood Marrow Transplant       Date:  2017-08-12       Impact factor: 5.742

4.  Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression.

Authors:  B F Coles; F Morel; C Rauch; W W Huber; M Yang; C H Teitel; B Green; N P Lang; F F Kadlubar
Journal:  Pharmacogenetics       Date:  2001-11

5.  Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients.

Authors:  M Ansari; M A Rezgui; Y Théoret; C R S Uppugunduri; S Mezziani; M-F Vachon; C Desjean; J Rousseau; M Labuda; C Przybyla; M Duval; M Champagne; C Peters; H Bittencourt; M Krajinovic
Journal:  Bone Marrow Transplant       Date:  2013-01-07       Impact factor: 5.483

Review 6.  Polymorphisms of GSTA1 contribute to elevated cancer risk: evidence from 15 studies.

Authors:  Qiwen Deng; Bangshun He; Yuqin Pan; Huiling Sun; Xian Liu; Jie Chen; Houqun Ying; Kang Lin; Hongxin Peng; Shukui Wang
Journal:  J BUON       Date:  2015 Jan-Feb       Impact factor: 2.533

7.  Regulation of JNK signaling by GSTp.

Authors:  V Adler; Z Yin; S Y Fuchs; M Benezra; L Rosario; K D Tew; M R Pincus; M Sardana; C J Henderson; C R Wolf; R J Davis; Z Ronai
Journal:  EMBO J       Date:  1999-03-01       Impact factor: 11.598

8.  GATA-and SP1-binding sites are required for the full activity of the tissue-specific promoter of the tal-1 gene.

Authors:  N Lecointe; O Bernard; K Naert; V Joulin; C J Larsen; P H Romeo; D Mathieu-Mahul
Journal:  Oncogene       Date:  1994-09       Impact factor: 9.867

9.  Resistance factors in colon cancer tissue and the adjacent normal colon tissue: glutathione S-transferases alpha and pi, glutathione and aldehyde dehydrogenase.

Authors:  J G Hengstler; T Böttger; B Tanner; B Dietrich; M Henrich; P G Knapstein; T Junginger; F Oesch
Journal:  Cancer Lett       Date:  1998-06-05       Impact factor: 8.679

10.  Differential effects of glutathione S-transferase pi (GSTP1) haplotypes on cell proliferation and apoptosis.

Authors:  Sarah L Holley; Anthony A Fryer; John W Haycock; Sarah E W Grubb; Richard C Strange; Paul R Hoban
Journal:  Carcinogenesis       Date:  2007-06-08       Impact factor: 4.944

View more
  2 in total

1.  Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study.

Authors:  Khalil Ben Hassine; Tiago Nava; Yves Théoret; Christa E Nath; Youssef Daali; Nastya Kassir; Victor Lewis; Robbert G M Bredius; Peter J Shaw; Henrique Bittencourt; Maja Krajinovic; Chakradhara Rao Satyanarayana Uppugunduri; Marc Ansari
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-08-28

Review 2.  Total Body Irradiation Forever? Optimising Chemotherapeutic Options for Irradiation-Free Conditioning for Paediatric Acute Lymphoblastic Leukaemia.

Authors:  Khalil Ben Hassine; Madeleine Powys; Peter Svec; Miroslava Pozdechova; Birgitta Versluys; Marc Ansari; Peter J Shaw
Journal:  Front Pediatr       Date:  2021-12-10       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.